Celgene Cellular Therapeutics (CCT) is at the forefront of cell therapy research and development. Our lead cell therapy candidates are derived from healthy, full-term placenta, a remarkable organ shared by mother and baby. From this immunologically privileged source, we have generated novel cell therapy candidates with immunomodulatory, anti-inflammatory, angiogenic and reparative properties. CCTs placenta-derived adherent cells (PDAC cells) have been extensively characterized (see our Publications) and display multiple activities including the ability to stimulate natural repair processes, with the potential to transform the treatment of a broad range of serious debilitating diseases including autoimmune, vascular and neurodegenerative disorders. Specific formulations of PDAC cells are our lead clinical candidates PDA-001 (intravenous) and PDA-002 (intramuscular), currently in clinical trials for Crohns disease, Peripheral Artery Disease with Diabetic Foot Ulcer and other indications. Cell therapy research teams focus on the discovery and early development of novel cell-based therapeutics. We have developed a portfolio of unique clinical candidates with broad therapeutic potential, including human placenta-derived stem cells (HPDSC), natural killer (NK) cells and amnion-derived adherent cells (AMDAC cells). We are industry leaders in adult stem cell isolation, cell culture, characterization, functional interpretation and translational medicine. Our state-of-the-art in vitro, preclinical and translational biology approaches … Continue reading →

Autologous (autologous refers to cells, tissues or even growth factors that are re-implanted in the same individual as they come from, another words patient receives his or her own cells) cell therapy injections is a by-product of blood that is rich in Growth factors and platelets. Until now, its use has been confined to the hospital setting. This was due mainly to the cost of separating the cells from the blood and the large amount of blood needed to produce a suitable quantity of cells. New technology permits the doctor to harvest and produce a sufficient quantity of cells from only 30-50 cc of blood drawn from the patient while they are in the office setting. It takes about 20 minutes to harvest these cells prior to injection. These cells allow the body to take advantage of the normal healing pathways at a greatly accelerated rate. During the healing process, the body rushes many cells and cell-types to the injected area in order to accelerate the healing process. These cells perform many functions, including release of growth factors (GF) into the diseased or arthritic and injured sites. Another main function is attracting Mesenchymal Stem Cells to the damaged area. These … Continue reading →

1102 Bates Street, Suite 1670 Houston, Texas 77030 The GMP Facilities at the Center for Cell and Gene Therapy at Baylor College of Medicine are among the largest and most modern in the United States. Manufacturing of therapeutic biologics has existed at Baylor for more than twenty years, and is now centralized in 19,000 square feet on the 16th floor of the Feigin Center at Texas Childrens Hospital. This facility opened in 2010 and contains 22 ISO 7 clean room suites supported by dedicated space for cell and product cold storage, flow cytometric analysis, quality control testing, data management and storage and quality assurance activities. The staff has extensive experience in GMP manufacturing of a wide variety of products and intermediates for cellular therapies and of viral and non-viral vectors, and master and working cell banks. Manufacturing and testing supports more than 30 investigator-sponsored INDs conducted at the Texas Medical Center and institutions around the United States. Products have also been prepared under contract for researchers in Europe, Asia and Australia. The range of products that have been manufactured is shown under the Vector and Cell Therapy Facilitypages. The facility is also accredited by the Foundation for the Accreditation of … Continue reading →

January 20, 2016 04:30 ET | Source: Transparency Market Research Albany, NY, Jan. 20, 2016 (GLOBE NEWSWIRE) -- Cell separation technologies make it possible to isolate target cells from a mixture of various cells. The growing prevalence of chronic diseases has fuelled the demand for cell therapies to understand the cause of the diseases. This has augmented the growth of the global cell separation technologies market. The overall market was worth US$1.7 bn in 2012. Rapidly growing patient pool and increase in research and development activities by biotechnology companies are expected to expand the market at a CAGR of 9.7% during the period between 2013 and 2019. The global cell separation technologies market is anticipated to reach a valuation of US$3.3 bn by 2019. Initiatives adopted by governments worldwide aimed at improving the biotechnology sector boost the growth of the global cell separation technologies market. The growing prevalence of diseases such as cancer has escalated the demand for cell therapy. However, the market is expected to be restrained by disputes related to patent rights over magnetic activated cell sorting (MACS) technique. The overall market has huge opportunity to grow with technological advancements. Browse Research Report on Cell Separation Technologies Market: … Continue reading →

Adult (Somatic) stem cells are unspecialized cells that are found in different parts of the body and, depending on the source tissue, have different properties. Adult stem cells are capable of self-renewal and give rise to daughter cells that are specialized to form the cell types found in the original body part. Adult stem cells are multipotent, meaning that they appear to be limited in the cell types that they can produce based on current evidence. However, recent scientific studies suggest that adult stem cells may have more plasticity than originally thought. Stem cell plasticity is the ability of a stem cell from one tissue to generate the specialized cell type(s) of another tissue. For example, bone marrow stromal cells are known to give rise to bone cells, cartilage cells, fat cells and other types of connective tissue (which is expected), but they may also differentiate into cardiac muscle cells and skeletal muscle cells (this was not initially thought possible). Hematopoietic stem cells that give rise to all blood and immune cells are today the most understood of the adult stem cells. Hematopoietic stem cells from bone marrow have been providing lifesaving cures for leukemia and other blood disorders for … Continue reading →

What if doctors could grow a new working inner ear from a persons own skin cells? Or repair the damaged inner ear from within? Solving this profound mystery is the driving force behind stem cell research and the promise of tissue engineering in otolaryngology. While hearing aids and cochlear implants can provide good recovery of hearing function, the development of a biological method to repair the damaged cochlea has the potential to restore normal hearing without any type of prosthesis. One approach to restore hearing might be to surgically place stem cells within the cochlea in such a way that they would fuse with the remaining cochlear structures and develop and function as hair cells. Scientists believe this is a viable approach because, unlike most organs that are destroyed by disease, the inner ear remains structurally intactonly the hair cells are lost. By mimicking the steps involved in the formation of embryonic mouse ears, Stanford scientists have produced stem cells in the laboratory that look and act very much like hair cells, the sensory cells that normally reside in the inner ear. If they can generate hair cells in the millions, it could lead to significant scientific and clinical advances … Continue reading →